- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077401
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study (READ 3)
March 20, 2017 updated by: Johns Hopkins University
The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with diabetic macular edema (DME).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
152
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Retina Vitreous Associates
-
LaJolla, California, United States, 92037
- University of California San Diego
-
Los Angeles, California, United States, 90033
- Doheny Eye Institute
-
Oakland, California, United States, 94609
- East Bay Retina Institute
-
Torrance, California, United States, 90503
- Retina Macula Institute
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33334
- Retina Group of Florida
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96815
- Retina Institute of Hawaii
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Illinois Retina Associates
-
-
Kansas
-
Prairie Village, Kansas, United States, 66208
- University of Kansas
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University Wilmer Eye Institute
-
-
Pennsylvania
-
Kingston, Pennsylvania, United States, 18704
- Eye Care Specialists
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Black Hills Eye Institute
-
-
Texas
-
Arlington, Texas, United States, 76012
- Texas Retina Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Signed informed consent and authorization of use and disclosure of protected health information
- Age ≥18 years
- Diagnosis of diabetes mellitus (type 1 or type 2)
- Serum HbA1c ≥ 5.5% within 12 months of randomization. Retinal thickening secondary to diabetes mellitus (diabetic macular edema) involving the center of the fovea
- Diagnosis must be confirmed by fluorescein angiography and OCT images
- Foveal thickness of ≥ 250 μm,
- Best corrected visual acuity score in the study eye of 20/40 to 20/320 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters). The non-study eye must be ≥ 20 letters (approximate Snellen equivalent 20/400).
- In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from DME and not from other obvious causes of decreased vision If a female of childbearing potential, a negative pregnancy test and commitment to the use of at least two forms of effective contraception (birth control) for the duration of the study are necessary.
Exclusion Criteria:
- Panretinal photocoagulation or macular photocoagulation within 3 months of study entry in the study eye
- Use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 3 months of study entry
- Previous participation in a study and receipt of anti-angiogenic drugs (pegaptanib sodium, ranibizumab, bevacizumab, anecortave acetate, protein kinase C inhibitor, etc.) within 2 months of study entry
- Proliferative diabetic retinopathy in the study eye, with the exceptions of
- Inactive, fibrotic proliferative diabetic retinopathy that has regressed following panretinal laser photocoagulation OR
- Tufts of neovascularization elsewhere (NVE) less than one disc area with no vitreous hemorrhage
- Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by optical coherence tomography (OCT)
- Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), macular ischemia, or organized hard exudate plaque
- Ocular disorders in the study eye that may confound interpretation of study results, including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., age related macular degeneration (AMD), ocular histoplasmosis, or pathologic myopia)
- Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the first 6-month study period
- Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum- Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other intraocular surgery within 3 months preceding Day 0.
- History of vitreoretinal surgery in the study eye within 3 months of study entry
- Uncontrolled glaucoma (defined as intraocular pressure ≥30 mm Hg despite treatment with anti-glaucoma medications)
- Blood pressure exceeding 180/100 (sitting) during the screening period
- Uncontrolled diabetes mellitus, as evidenced by glycosylated hemoglobin (HbA1c) value >13%
- Renal failure requiring dialysis or renal transplant
- Premenopausal women unwilling to commit to adequate contraception
- History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications
- International normalized ratio (INR) ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin or other anticoagulants is not an exclusion
- History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.
- Have a history of hypersensitivity to ranibizumab or any of its components
- Have the presence of active malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
Other
- Inability to comply with study or follow-up procedures
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
- Participation in another simultaneous medical investigation or trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranibizumab 0.5mg
Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
|
Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
Other Names:
|
Experimental: Ranibizumab 2.0 mg
Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
|
Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Deaths Due to Myocardial Infarction
Time Frame: 6 Months
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Best Corrected Visual Acuity From Baseline to Month 6
Time Frame: baseline 6 Months
|
Mean change in best corrected visual acuity (BCVA) (ETDRS) at 4 meters in the study eye over time through month 6.
|
baseline 6 Months
|
Mean Change in Retinal Thickness at Month 6
Time Frame: baseline to6 Months
|
baseline to6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Diana V Do, MD, Truhlsen Eye Institute, University of Nebraska Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
March 1, 2012
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
February 26, 2010
First Submitted That Met QC Criteria
February 26, 2010
First Posted (Estimate)
March 1, 2010
Study Record Updates
Last Update Posted (Actual)
April 28, 2017
Last Update Submitted That Met QC Criteria
March 20, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA_00034586
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted